Symphony Asset Management LLC trimmed its stake in Catalent Inc (NASDAQ:CTLT) by 42.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,566 shares of the company’s stock after selling 13,144 shares during the period. Symphony Asset Management LLC’s holdings in Catalent were worth $616,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA increased its position in shares of Catalent by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,909 shares of the company’s stock worth $309,000 after purchasing an additional 130 shares during the last quarter. Aperio Group LLC increased its position in shares of Catalent by 0.8% in the second quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after purchasing an additional 190 shares during the last quarter. Capstone Asset Management Co. increased its position in shares of Catalent by 2.3% in the second quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after purchasing an additional 230 shares during the last quarter. Advantus Capital Management Inc increased its position in shares of Catalent by 3.0% in the first quarter. Advantus Capital Management Inc now owns 15,972 shares of the company’s stock worth $452,000 after purchasing an additional 468 shares during the last quarter. Finally, State Treasurer State of Michigan increased its position in shares of Catalent by 1.0% in the first quarter. State Treasurer State of Michigan now owns 50,700 shares of the company’s stock worth $1,436,000 after purchasing an additional 500 shares during the last quarter.

In other Catalent news, SVP Christine Dolan sold 1,594 shares of Catalent stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Several research analysts recently weighed in on CTLT shares. Wells Fargo & Company restated an “outperform” rating and issued a $39.00 price objective (up from $30.00) on shares of Catalent in a research report on Thursday, August 31st. J P Morgan Chase & Co restated a “buy” rating and issued a $40.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research report on Tuesday, August 22nd. William Blair restated an “ourperform” rating on shares of Catalent in a research report on Tuesday, August 29th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $38.00 price objective (up from $35.00) on shares of Catalent in a research report on Tuesday, August 29th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $36.80.

Catalent Inc (CTLT) opened at 40.59 on Thursday. The firm’s 50-day moving average is $36.52 and its 200-day moving average is $33.34. The company has a market capitalization of $5.08 billion and a PE ratio of 46.66. Catalent Inc has a 12 month low of $21.83 and a 12 month high of $42.22.

Catalent (NASDAQ:CTLT) last released its quarterly earnings data on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The business had revenue of $616.90 million for the quarter, compared to the consensus estimate of $547.48 million. During the same quarter in the previous year, the company posted $0.52 EPS. The company’s revenue was up 15.9% compared to the same quarter last year. Equities analysts anticipate that Catalent Inc will post $1.61 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/14/catalent-inc-ctlt-shares-sold-by-symphony-asset-management-llc.html.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).

Institutional Ownership by Quarter for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.